angiotensin ii has been researched along with Atrial Fibrillation in 119 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (28.57) | 29.6817 |
| 2010's | 52 (43.70) | 24.3611 |
| 2020's | 33 (27.73) | 2.80 |
| Authors | Studies |
|---|---|
| Can, J; Hao, S; Ning, Z; Qiang, X; Wu, Y | 1 |
| Dong, X; Huang, YT; Luo, LY; Wang, HS; Wang, ZS; Xu, DY; Xu, YL; Xue, XD; Yu, LM; Zhao, JK; Zhao, QS; Zhou, ZJ | 1 |
| Han, X; Li, HH; Li, PB; Teng, F; Yu, P; Zhang, YL | 1 |
| Ji, L; Liu, D; Liu, G; Liu, M; Ono, K; Wang, L; Wei, M; Yin, Y; Zhan, Y; Zheng, M; Zhou, X | 1 |
| Bi, HL; Liao, ZQ; Shen, TT; Shi, L; Su, ZL; Xia, YL; Xie, X; Zhang, Y | 1 |
| Cao, L; Cong, H; Du, X; Geng, J; Hu, Y; Wang, J; Zhang, R; Zhang, Y; Zhao, X; Zheng, L | 1 |
| Ge, C; He, Y; Liang, Y; Zhao, Y | 1 |
| Blanco-Favela, F; Chávez-Sánchez, L; González-Hermosillo, A; Madrid-Miller, A; Martinez-Flores, E; Moreno-Ruiz, LA; Vazquez-González, W; Wacher-Rodarte, N; Zamorano-Velázquez, N | 1 |
| Kong, Y; Li, L; Li, W; Lou, Q; Yang, W; Zhang, L; Zhang, W; Zhao, H | 1 |
| Aonuma, K; Ieda, M; Isoda, H; Li, S; Murakata, Y; Murakoshi, N; Nogami, A; Okabe, Y; Tajiri, K; Tominaga, K; Xu, D; Yuan, Z | 1 |
| Guo, SB; Han, X; Li, HH; Yin, WP; Zhang, YL; Zhao, YX | 1 |
| Chen, B; Chen, X; Cui, C; Hall, DD; Hong, J; Huang, J; Li, D; Li, F; Lu, M; Pan, Z; Shi, L; Song, L; Song, LS; Wang, B; Wang, J; Wang, Y; Yang, K; Zhang, L; Zhao, S | 1 |
| Chen, K; Fu, H; Ma, J; Song, W; Wang, X; Zang, X; Zhao, Y; Zhao, Z | 1 |
| Cai, X; Li, M; Liang, Z; Yang, W; Zhong, Y | 1 |
| Chen, L; He, Z; Huang, Y; Li, Y; Lu, F; Lyu, F; Lyu, X; Mo, Q; Qin, Q; Xu, H | 1 |
| Cao, W; Chen, L; Fang, G; Gu, Y; Li, Y; Liu, L; Mo, B; Song, S; Wan, Y; Wang, Q; Wang, Y; Yu, Y; Zhang, R | 1 |
| Che, H; Ge, S; Gong, W; Guo, Z; Shen, Z; Shi, Y; Sun, F; Zhang, C | 1 |
| Bi, HL; Chen, C; Li, HH; Li, Z; Shu, Q; Yan, X; Yang, J; Yang, XL; Zhang, YL | 1 |
| Chen, Y; Ge, Z; Wang, B; Xie, Y; Yan, Y; Zhang, X; Zhang, Y; Zhou, L | 1 |
| Deng, CY; Guo, HM; Li, X; Liu, FZ; Liu, Y; Rao, F; Wang, ZY; Wei, W; Wu, SL; Xue, YM; Yang, H; Zhang, MZ | 1 |
| Okamura, K; Okuda, T; Shirai, K; Takamiya, Y; Urata, H | 1 |
| Cao, HJ; Chen, C; Guo, SB; Han, X; Li, HH; Li, PB; Liu, Y; Teng, F; Xia, YL; Yan, X; Yang, J; Zhang, YL | 1 |
| Abe, I; Arakane, M; Daa, T; Ishii, Y; Kira, S; Kondo, H; Miyoshi, M; Nakagawa, M; Oniki, T; Takahashi, N; Teshima, Y; Yufu, K; Zhan, Y | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Chen, Y; Li, X; Liu, Q; Qiao, X; Zhang, L | 1 |
| Fu, X; Song, T; Wang, H; Wang, X; Zhao, J; Zhao, Y | 1 |
| An, X; Liu, Y; Liu, YJ; Lv, H; Niu, XH; Tan, R; Xia, YL; Yang, X; Yin, X | 1 |
| Balestrieri, A; Barcellona, D; Caocci, G; Castagnola, M; Cau, R; Coghe, F; Coni, P; D'Andrea, F; Faa, G; Fanni, D; Gerosa, C; La Nasa, G; Ledda, F; Marongiu, F; Orru, G; Piras, M; Ronchi, A; Saba, L; Suri, JS | 1 |
| Fukuda, D; Hara, T; Ise, T; Kusunose, K; Matsuura, T; Sata, M; Soeki, T; Tobiume, T; Uematsu, E; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K | 1 |
| He, X; Liang, P; Liu, D; Wang, G; Wu, H | 1 |
| Alatawi, Y; Alghamdi, BS; Alshehri, FS; Balabagno, AO; Chen, Y; Durmanova, V; Evangelista, LS; Hromadka, T; Javor, J; Ji, Q; Jiao, J; Kralova, M; Kurdi, M; Labban, S; Li, X; Li, Y; Lv, Q; Minarik, G; Ocenasova, A; Pagsibigan, JS; Parnicka, Z; Reznakova, V; Shawkatova, I; Shen, ZJ; Tian, X; Tu, S; Tuazon, JA; Vaseckova, B; Wang, XY; Wang, Z; Xue, Y; Zeng, LX; Zhang, S; Zhang, ZH; Zuo, C | 1 |
| Li, CY; Li, SN; Xi, H; Zhang, JR; Zhao, L; Zhou, L | 1 |
| Fan, XW; Fu, HX; Hu, GL; Hu, J; Kong, B; Li, L; Liu, JJ; Song, WF; Wang, SL; Wu, JT; Yan, LJ; Yang, HT; Zhang, JJ; Zhang, LM | 1 |
| Hu, HJ; Liu, CH; Su, H; Tang, YX; Zhao, JB; Zou, T | 1 |
| Fu, H; Liu, M; Shuai, W; Wang, H; Wang, X | 1 |
| Chen, X; Liu, X; Wang, Q; Wu, S; Zhang, D; Zheng, Y | 1 |
| Chen, J; Chen, Y; Li, C; Li, Y; Wang, Q; Wang, Y; Yu, Y; Zhang, P | 1 |
| Cheng, Z; Qiao, G; Xia, D; Zhang, G | 1 |
| Bukowska, A; Corradi, D; Goette, A; Hammwöhner, M; Mahardhika, W | 1 |
| Bai, J; Che, YL; Li, HH; Li, J; Wang, S; Yang, XL; Yang, YZ; Zhang, YL | 1 |
| Cai, H; Gao, Z; Li, H; Song, K; Wang, Y | 1 |
| Nattel, S | 2 |
| Huang, H; Kong, B; Liu, Y; Quan, D; Shen, C; Shuai, W; Wang, G; Xiong, L | 1 |
| Belke, DD; Egom, EE; Jansen, HJ; Kirkby, AW; Mackasey, M; Moghtadaei, M; Rafferty, SA; Rose, RA; Tuomi, JM | 1 |
| Bai, J; Li, HH; Li, J; Lin, QY; Liu, RS; Wang, S; Yu, XH; Zhang, YL | 1 |
| Egom, EE; Jansen, HJ; Kaur, J; Kirkby, AW; Liu, Y; Mackasey, M; Moghtadaei, M; Rafferty, SA; Rose, RA; Tuomi, JM | 1 |
| Dong, W; Fang, X; Guo, H; Li, H; Liang, J; Pan, R; Shan, Z; Wu, S; Xiao, Z; Yang, J; Yang, Z; Yuan, S; Zheng, XL; Zhu, J | 1 |
| Cao, F; Ding, WM; Li, Z; Yan, L; Zhao, QY | 1 |
| Berrino, L; Capuano, A; De Angelis, A; Mascolo, A; Rosano, GMC; Rossi, F; Scavone, C; Sessa, M; Urbanek, K | 1 |
| Fukui, A; Hara, M; Kume, O; Masaki, T; Nakada, C; Saikawa, T; Shinohara, T; Takahashi, N; Teshima, Y | 1 |
| Aderkast, C; Bukowska, A; Busch, M; Chilukoti, RK; Felix, SB; Goette, A; Homuth, G; Lendeckel, U; Mostertz, J; Völker, U; Wolke, C | 1 |
| Cai, H; Chen, H; Liu, D; Ping, P; Weiss, JN; Youn, JY; Zhang, J; Zhang, Y | 1 |
| Dai, Z; Huang, C; Huang, H; Tang, Y; Wang, X; Xiao, J; Yu, S; Zhao, Q | 1 |
| Anderson, ME; Behunin, AC; Chen, B; Dobrev, D; El-Accaoui, RN; Gao, Z; Guan, X; Koval, OM; Li, N; Luczak, ED; Maier, LS; Neef, S; Purohit, A; Rokita, AG; Song, LS; Sowa, T; Stefansdottir, H; Swaminathan, PD; Voigt, N; Wehrens, XH; Weiss, RM; Yang, B | 1 |
| Goette, A; Lendeckel, U; Wolke, C | 2 |
| Cheng, XW; Fujita, M; Inden, Y; Inoue, A; Kuzuya, M; Kyo, S; Murohara, T; Okumura, K; Shi, GP; Shimano, M; Taguchi, N; Takeshita, K; Yamamoto, T; Yoshida, N | 1 |
| Hong, T; Huanzhang, S; Wenxia, Z; Xijun, X; Yongjun, Q | 1 |
| Adam, M; Andrié, RP; Baldus, S; Deuschl, F; Friedrichs, K; Klinke, A; Mollenhauer, M; Nickenig, G; Ravekes, T; Remane, L; Rudolph, TK; Rudolph, V; Schrickel, JW; Stöckigt, F; Willems, S | 1 |
| Cartwright, EJ; Chen, S; Christoffels, V; Davies, L; Dong, N; Fraser, JA; Hao, G; Huang, CL; Jin, J; Lei, M; Ravens, U; Shen, W; Shi, Y; Tsui, H; Wang, X; Wang, Y; Wu, J; Zhang, H; Zhang, Y | 1 |
| Huang, JH; Wang, HS; Xue, XD | 1 |
| Liu, B; Wang, G; Wang, J | 1 |
| Chen, FK; Chen, XP; Guo, HY; Li, J; Li, YG; Liang, Z; Lin, K; Liu, LF; Shan, ZL; Shi, XM; Wang, YT | 1 |
| Chen, XQ; Guo, M; Jiang, WF; Liu, F; Liu, X; Wang, QX; Zhan, YY; Zhang, DL; Zhang, MJ; Zhao, L; Zhou, L | 1 |
| Ahmad, S; Deal, D; Dell'Italia, LJ; Ferrario, CM; Groban, L; Kon, ND; Nagata, S; Simington, SW; Varagic, J; VonCannon, JL; Wang, H | 1 |
| Ambrozova, G; Baldus, S; Freeman, BA; Friedrichs, K; Kaur, JJ; Klinke, A; Kubala, L; Martiskova, H; Matthes, B; Mollenhauer, M; Pekarova, M; Ravekes, T; Rudolph, TK; Rudolph, V; Schwoerer, A; Woodcock, SR | 1 |
| Cheng, QJ; Li, XX; Liu, CL; Wang, JH; Wang, YH; Yuan, CT | 1 |
| Böhm, M; Dhein, S; Hohl, M; Kabiri, M; Linz, D; Reil, JC; Ruf, S; Sadowski, T; Schotten, U; Verheule, S; Wohlfart, P | 1 |
| Jiang, L; Liang, ZG; Lin, X; Yao, H | 1 |
| Bao, M; Cao, Q; Dai, M; Hu, D; Huang, C; Huang, H; Tang, Y; Wang, X; Yu, L; Zhang, Y | 1 |
| Cheng, YJ; Gao, XR; Liu, LJ; Lu, GH; Tang, K; Wu, SH; Xu, CG; Xu, Z; Yao, FJ | 1 |
| Agbaedeng, T; Elliott, AD; Lau, DH; Mahajan, R; Sanders, P; Thanigaimani, S | 1 |
| Wang, HS; Wu, HB; Xu, S; Xu, YL; Xue, XD; Zhang, J | 1 |
| Huang, SK; Lai, LP; Lin, CS; Lin, JL; Tsai, CT | 1 |
| Cooper, D; Fazio, G; Guttilla, D; Novo, G; Novo, S | 1 |
| Nattel, S; Van Wagoner, DR | 1 |
| Hasenfuss, G; Kockskämper, J; Pieske, B; Rübertus, SU; Schmitto, JD; Schöndube, FA; von Lewinski, D; Zhu, D | 1 |
| Durin, O; Inama, G; Pedrinazzi, C | 1 |
| Darbar, D; Donahue, BS; Ellinor, PT; Kaiser, DW; Kannankeril, PJ; MacRae, CA; Makino, S; Roden, DM; Wasserman, BS; Watanabe, H | 1 |
| Adam, O; Ameling, S; Böhm, M; Grube, M; Hohl, M; Kroemer, HK; Laufs, U; Lavall, D; Rosenkranz, S; Schäfers, HJ; Sussman, MA; Theobald, K | 1 |
| Kumagai, K | 1 |
| Aihara, K; Akaike, M; Ikeda, Y; Ishikawa, K; Iwase, T; Matsumoto, T; Sata, M; Soeki, T; Sumitomo-Ueda, Y; Yagi, S; Yoshida, S | 1 |
| Andrié, RP; Baldus, S; Böger, RH; Didié, M; Ehmke, H; Eschenhagen, T; Freeman, BA; Friedrichs, K; Fu, X; Hazen, SL; Hirsch-Hoffmann, B; Klingel, K; Klinke, A; Lau, D; Lewalter, T; Meinertz, T; Nickenig, G; Reichenspurner, H; Rudolph, TK; Rudolph, V; Schrickel, JW; Schwoerer, AP; Seniuk, A; Sydow, K; Szoecs, K; Treede, H; von Leitner, EC; Wenzel, U; Willems, S; Zimmermann, WH | 1 |
| Abidin, N; Choudhury, R; Garratt, CJ; Hall, MC; Kirubakaran, S; Peters, NS | 1 |
| Duan, DD; Gao, X; He, X; Lin, J; Ma, H; Peng, L; Wang, S; Zhu, Y | 1 |
| Adam, O; Ameling, S; Böhm, M; Grube, M; Kroemer, HK; Laufs, U; Lavall, D; Schäfers, HJ; Theobald, K | 1 |
| Hong, CY; Hou, SM; Ko, WC; Lai, LP; Lee, CF; Lin, CH; Ong, ET; Tsai, CT | 1 |
| Li, G; Liu, Y; Sharma, D; Xu, G; Xu, Y | 1 |
| Aoyama, Y; Fukaya, H; Izumi, T; Kiryu, M; Kishihara, J; Masaki, Y; Niwano, H; Niwano, S | 1 |
| Dai, Z; Huang, C; Wang, X; Xiao, J; Yu, S; Zhao, Q; Zou, M | 1 |
| Jiang, L; Li, M; Li, N; Li, Y; Liu, Y; Qian, Y; Tang, H; Xiao, X; Zhou, W | 1 |
| Albåge, A; Berglund, H; Kennebäck, G; van der Linden, J | 1 |
| Cardin, S; Leung, TK; Li, D; Nattel, S; Thorin, E; Thorin-Trescases, N | 1 |
| Boldt, A; Dhein, S; Garbade, J; Gummert, JF; Hindricks, G; Kottkamp, H; Lauschke, J; Weigl, J; Wetzel, U | 1 |
| Goette, A; Lendeckel, U | 2 |
| Bernstein, KE; Campbell, DJ; Capecchi, MR; Dudley, SC; Fuchs, S; Hoit, BD; Kasi, VS; Keshelava, G; Lewis, W; Xiao, HD; Zhao, H | 1 |
| Goette, A; Klein, HU; Lendeckel, U | 1 |
| Allessie, M; Blaauw, Y; Eijsbouts, S; Neuberger, HR; Schotten, U; van Hunnik, A; Verheule, S | 1 |
| DiDomenico, RJ; Massad, MG | 1 |
| Crijns, HJ; Folkeringa, RJ; Tieleman, RG | 1 |
| Hemels, ME; Van den Berg, MP; Van Gelder, IC; Van Tintelen, JP; Van Veldhuisen, DJ; Wiesfeld, AC | 1 |
| Brandt, MC; Er, F; Gassanov, N; Hoppe, UC; Lindner, M; Michels, G | 1 |
| Ding, WG; Horie, M; Isono, T; Matsuura, H; Omatsu-Kanbe, M; Toyoda, F; Zankov, DP | 1 |
| D'Alessandro, A; Dobrev, D; Goette, A; Hammwöhner, M; Kirchhof, P | 1 |
| Heusch, G; Schulz, R | 1 |
| Dulger, H; Erbilen, E; Guler, N; Gumrukcuoglu, HA; Kutay, V; Ozkara, C; Sahin, M | 1 |
| Bukowska, A; Goette, A; Lendeckel, U | 1 |
| Anné, W; Beckers, F; Ector, H; Heidbüchel, H; Holemans, P; Lenaerts, I; Roskams, T; Willems, R | 1 |
| Hara, M; Nakagawa, M; Ooie, T; Saikawa, T; Shimada, T; Shinohara, T; Takahashi, N; Wakisaka, O; Yonemochi, H; Yoshimatsu, H | 1 |
| Chiang, FT; Hsieh, CS; Hsu, KL; Hwang, JJ; Kuo, KT; Lai, LP; Lin, JL; Tsai, CT; Tseng, CD; Tseng, YZ | 1 |
| Camm, J; Savelieva, I | 1 |
| Chen, WP; Chiang, FT; Hsu, KL; Hwang, JJ; Lai, LP; Lin, JL; Tsai, CT; Tseng, CD; Tseng, YZ | 1 |
| Lin, CS; Pan, CH | 1 |
| Arakawa, K; Gondo, N; Ideishi, M; Kumagai, K; Nakashima, H; Urata, H | 1 |
| Albåge, A; Bengtsson, L; Berglund, H; Kennebäck, G; Lindblom, D; van der Linden, J | 1 |
| Cardin, S; Leung, TK; Li, D; Nattel, S; Pang, L; Shinagawa, K; Wang, Z | 1 |
| Ector, H; Heidbüchel, H; Holemans, P; Sipido, KR; Van de Werf, F; Willems, R | 1 |
20 review(s) available for angiotensin ii and Atrial Fibrillation
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Atrial Fibrillation; Blood Coagulation; Capillary Permeability; Cardiomyopathies; COVID-19; Cytokine Release Syndrome; Cytokines; Endothelium, Vascular; Fibroblasts; Fibrosis; Humans; Liver Cirrhosis; Myocarditis; Receptors, Coronavirus; Renin-Angiotensin System; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Thrombosis; Virus Internalization | 2020 |
Atrial thrombogenesis in atrial fibrillation : Results from atrial fibrillation models and AF-patients.
Topics: Age Factors; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Remodeling; Disease Models, Animal; Endocardium; Heart Atria; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice, Transgenic; Platelet Activation; Risk Assessment; Thromboembolism | 2018 |
Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation.
Topics: Angiotensin II; Atrial Fibrillation; Collagen; Connective Tissue Growth Factor; Extracellular Matrix; Fibroblasts; Fibrosis; Heart Atria; Humans; Ion Channels; MicroRNAs; Myocytes, Cardiac; Platelet-Derived Growth Factor; Signal Transduction; Transforming Growth Factor beta1 | 2017 |
Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?
Topics: Angiotensin I; Angiotensin II; Atrial Fibrillation; Atrial Remodeling; Humans; Peptide Fragments | 2020 |
Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Humans; NADPH Oxidases; Oxidative Stress | 2013 |
Molecular mechanisms of atrial fibrosis: implications for the clinic.
Topics: Angiotensin II; Atrial Fibrillation; Fibrosis; Heart Atria; Humans; Signal Transduction; Transforming Growth Factor beta1 | 2017 |
The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Evidence-Based Medicine; Genotype; Humans; Mitogen-Activated Protein Kinase Kinases; Renin-Angiotensin System | 2008 |
[Non-antiarrhythmic pharmacological treatment of atrial fibrillation: focus on drugs acting on the renin-angiotensin system].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Atrial Function; Dogs; Humans; Renin-Angiotensin System | 2008 |
[Upstream approach for atrial fibrillation].
Topics: Amiodarone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Humans; Irbesartan; Tetrazoles | 2010 |
Atrial remodeling in atrial fibrillation and some related microRNAs.
Topics: Angiotensin II; Atrial Fibrillation; Calcium Channels; Heart Atria; Humans; MicroRNAs; Platelet-Derived Growth Factor; Potassium Channels, Inwardly Rectifying; Potassium Channels, Voltage-Gated; Transforming Growth Factor beta1; Vasoconstrictor Agents | 2011 |
Nonchannel drug targets in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Antioxidants; Atrial Fibrillation; Humans; Metalloproteases; Myocardium; Oxidative Stress; Thrombosis | 2004 |
Pharmacologic strategies for prevention of atrial fibrillation after open heart surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Cardiac Surgical Procedures; Digoxin; Humans; Postoperative Care; Risk Factors; Sotalol; Tachycardia, Supraventricular | 2005 |
Non-antiarrhythmic drugs to prevent atrial fibrillation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Cardiotonic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention | 2004 |
Genetic aspects of atrial fibrillation.
Topics: Aged; Angiotensin II; Atrial Fibrillation; Connexins; Coronary Disease; Gap Junction alpha-5 Protein; Heart Conduction System; Heart Failure; Humans; Polymorphism, Genetic | 2005 |
[New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].
Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Genetic Therapy; Heart Conduction System; Humans; Models, Cardiovascular; Practice Guidelines as Topic; Practice Patterns, Physicians'; Treatment Outcome | 2006 |
[Pathophysiology of atrial fibrillation: importance of the renin-angiotensin system].
Topics: Action Potentials; Angiotensin II; Animals; Anisotropy; Atrial Fibrillation; Connexins; Electrophysiology; Gap Junction alpha-5 Protein; Humans; Renin-Angiotensin System | 2006 |
Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling).
Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Drug Delivery Systems; Heart Atria; Humans; Inflammation Mediators; Oxidative Stress; Signal Transduction | 2007 |
Update on atrial fibrillation: part I.
Topics: Angiotensin II; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Fibrinolytic Agents; Humans; Risk Assessment; Stroke | 2008 |
Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Atrial Fibrillation; Endomyocardial Fibrosis; Heart Atria; Humans; Inflammation; Matrix Metalloproteinases; Models, Biological; Oxidative Stress; Peptide Fragments; ras GTPase-Activating Proteins; Signal Transduction; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta1; Ventricular Remodeling | 2008 |
4 trial(s) available for angiotensin ii and Atrial Fibrillation
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients.
Topics: Aged; Angiotensin II; Atrial Fibrillation; Diabetes Complications; Disease Progression; Double-Blind Method; Female; Glycation End Products, Advanced; Heart Atria; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptide Fragments; Pioglitazone; Procollagen; Thiazolidinediones | 2014 |
Fluvastatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation.
Topics: Angiotensin II; Atrial Fibrillation; Benzazepines; C-Reactive Protein; Case-Control Studies; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Function Tests; Humans; Indoles; Interleukin-6; Kidney; Liver; Male; Middle Aged; Prognosis; Renin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2016 |
Relationship between Angiotensin Converting Enzyme, Apelin, and New-Onset Atrial Fibrillation after Off-Pump Coronary Artery Bypass Grafting.
Topics: Aged; Angiotensin II; Apelin; Atrial Fibrillation; Bradykinin; C-Reactive Protein; Case-Control Studies; Coronary Artery Bypass, Off-Pump; Female; Humans; Inflammation; Intercellular Signaling Peptides and Proteins; Male; Malondialdehyde; Middle Aged; Multivariate Analysis; Oxidative Stress; Peptidyl-Dipeptidase A; Postoperative Complications; Postoperative Period; Preoperative Period; Retrospective Studies; Risk Factors | 2017 |
96 other study(ies) available for angiotensin ii and Atrial Fibrillation
| Article | Year |
|---|---|
LOXL2 Inhibitor Attenuates Angiotensin II-Induced Atrial Fibrosis and Vulnerability to Atrial Fibrillation through Inhibition of Transforming Growth Factor Beta-1 Smad2/3 Pathway.
Topics: Amino Acid Oxidoreductases; Angiotensin II; Animals; Atrial Fibrillation; Fibrosis; Humans; Male; Mice; Mice, Inbred C57BL; Smad2 Protein; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2022 |
Activation of PKG-CREB-KLF15 by melatonin attenuates Angiotensin II-induced vulnerability to atrial fibrillation via enhancing branched-chain amino acids catabolism.
Topics: Amino Acids, Branched-Chain; Angiotensin II; Atrial Fibrillation; Cyclic AMP Response Element-Binding Protein; Cyclic GMP-Dependent Protein Kinases; Humans; Kruppel-Like Transcription Factors; Melatonin | 2022 |
Time series proteome profile analysis reveals a protective role of citrate synthase in angiotensin II-induced atrial fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Citrate (si)-Synthase; Humans; Male; Mice; Mice, Inbred C57BL; Proteome; Time Factors | 2022 |
Pharmacological activation of estrogenic receptor G protein-coupled receptor 30 attenuates angiotensin II-induced atrial fibrosis in ovariectomized mice by modulating TGF-β1/smad pathway.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cardiomyopathies; Female; Fibroblasts; Fibrosis; Heart Atria; Mice; Mice, Inbred C57BL; Receptors, Estrogen; Receptors, G-Protein-Coupled; Smad Proteins; Transforming Growth Factor beta1 | 2022 |
Melatonin inhibits angiotensin II-induced atrial fibrillation through preventing degradation of Ang II Type I Receptor-Associated Protein (ATRAP).
Topics: Angiotensin II; Animals; Atrial Fibrillation; Melatonin; Mice; Proteasome Endopeptidase Complex; Receptor, Angiotensin, Type 1; Receptors, Melatonin | 2022 |
Angiotensin II Mediates Cardiomyocyte Hypertrophy in Atrial Cardiomyopathy via Epigenetic Transcriptional Regulation.
Topics: Angiotensin II; Atrial Fibrillation; Cardiomegaly; Cardiomyopathies; Chromatin; Epigenesis, Genetic; Humans; Myocytes, Cardiac; Signal Transduction | 2022 |
Silencing of TLR4 Inhibits Atrial Fibrosis and Susceptibility to Atrial Fibrillation via Downregulation of NLRP3-TGF-
Topics: Angiotensin II; Animals; Atrial Fibrillation; Collagen Type I; Down-Regulation; Fibrosis; Heart Atria; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Inbred SHR; RNA, Small Interfering; Toll-Like Receptor 4; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2022 |
Post-cardioversion time Course of Atrial Remodeling Markers and their Association with Recurrence in Subjects with Long-standing, Persistent Atrial Fibrillation.
Topics: Aldosterone; Angiotensin II; Atrial Fibrillation; Atrial Remodeling; Biomarkers; Electric Countershock; Humans; Recurrence; Treatment Outcome | 2022 |
CircCAMTA1 facilitates atrial fibrosis by regulating the miR-214-3p/TGFBR1 axis in atrial fibrillation.
Topics: Angiotensin II; Atrial Fibrillation; Collagen; Fibroblasts; Fibrosis; Humans; MicroRNAs; Receptor, Transforming Growth Factor-beta Type I | 2023 |
Novel preventive effect of isorhamnetin on electrical and structural remodeling in atrial fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Calcium; Heart Atria; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac | 2022 |
Adipose Triglyceride Lipase Deficiency Aggravates Angiotensin II-Induced Atrial Fibrillation by Reducing Peroxisome Proliferator-Activated Receptor α Activation in Mice.
Topics: Acyltransferases; Angiotensin II; Animals; Atrial Fibrillation; Fibrosis; Lipase; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR alpha | 2023 |
CIB2 Is a Novel Endogenous Repressor of Atrial Remodeling.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Fibrosis; Heart Atria; Mice; RNA | 2023 |
SHP-1 alleviates atrial fibrosis in atrial fibrillation by modulating STAT3 activation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Fibrosis; Heart Atria; Humans; Mice; Reactive Oxygen Species; STAT3 Transcription Factor; Transforming Growth Factor beta1 | 2023 |
COMP Improves Ang-II-Induced Atrial Fibrillation via TGF-β Signaling Pathway.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cartilage Oligomeric Matrix Protein; Fibrosis; Mice; Signal Transduction; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2023 |
[mRNA Expression Profile Changes in Angiotensin-Ⅱ-Induced Atrial Myocardial Fibrosis in Rats].
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cardiomyopathies; Collagen; Fibrosis; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2023 |
EZH2 as a novel therapeutic target for atrial fibrosis and atrial fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Enhancer of Zeste Homolog 2 Protein; Female; Fibroblasts; Fibrosis; Gene Expression Regulation; Heart Atria; Humans; Indoles; Male; Mice; Middle Aged; Pyridones | 2019 |
LncRNA NRON alleviates atrial fibrosis through suppression of M1 macrophages activated by atrial myocytes.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cells, Cultured; Collagen Type I; Culture Media, Conditioned; Fibroblasts; Fibrosis; Heart Atria; Macrophage Activation; Macrophages; Mice; Myocytes, Cardiac; RAW 264.7 Cells; RNA, Long Noncoding | 2019 |
Inhibition of UCHL1 by LDN-57444 attenuates Ang II-Induced atrial fibrillation in mice.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Blood Pressure; Heart Atria; Indoles; Male; Mice; Oximes; Reactive Oxygen Species; Signal Transduction; Ubiquitin Thiolesterase | 2020 |
MFGE8 attenuates Ang-II-induced atrial fibrosis and vulnerability to atrial fibrillation through inhibition of TGF-β1/Smad2/3 pathway.
Topics: Angiotensin II; Animals; Antigens, Surface; Atrial Fibrillation; Cell Movement; Cell Proliferation; Cells, Cultured; Fibroblasts; Fibrosis; Gene Expression Regulation; Heart Atria; Humans; Integrin beta3; Male; Milk Proteins; Models, Biological; Protein Binding; Rats, Sprague-Dawley; Recombinant Proteins; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2020 |
High hydrostatic pressure induces atrial electrical remodeling through angiotensin upregulation mediating FAK/Src pathway activation.
Topics: Angiotensin I; Angiotensin II; Animals; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Atrial Remodeling; Cell Line, Tumor; Focal Adhesion Kinase 1; Humans; Hydrostatic Pressure; Mice; Myocytes, Cardiac; Peptide Fragments; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; src-Family Kinases; Up-Regulation; Valsartan | 2020 |
Elevated chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes was observed in the patient of atrial fibrillation.
Topics: Action Potentials; Aged; Aged, 80 and over; Angiotensin II; Atrial Fibrillation; Atrial Remodeling; Biomarkers; Case-Control Studies; Chymases; Cross-Sectional Studies; Female; Heart Rate; Humans; Leukocytes, Mononuclear; Male; Middle Aged | 2020 |
Chemokine Receptor CXCR-2 Initiates Atrial Fibrillation by Triggering Monocyte Mobilization in Mice.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Blood Pressure; Chemokine CXCL1; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Phenylurea Compounds; Receptors, Interleukin-8B; Superoxides | 2020 |
A traditional herbal medicine rikkunshito prevents angiotensin II-Induced atrial fibrosis and fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cardiotonic Agents; Drugs, Chinese Herbal; Fibrosis; Heart Atria; Male; Mice, Inbred C57BL | 2020 |
Apelin-13 regulates angiotensin ii-induced Cx43 downregulation and autophagy via the AMPK/mTOR signaling pathway in HL-1 cells.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Atrial Fibrillation; Autophagy; Cell Line; Connexin 43; Down-Regulation; Drug Interactions; Intercellular Signaling Peptides and Proteins; Mice; Myocytes, Cardiac; Signal Transduction; TOR Serine-Threonine Kinases; Vasoconstrictor Agents | 2020 |
Long non-coding RNA LICPAR regulates atrial fibrosis via TGF-β/Smad pathway in atrial fibrillation.
Topics: Angiotensin II; Atrial Fibrillation; Biomarkers; Cell Proliferation; Cell Survival; Fibroblasts; Fibrosis; Heart Atria; Humans; Middle Aged; RNA, Long Noncoding; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Up-Regulation | 2020 |
Platelets Promote Ang II (Angiotensin II)-Induced Atrial Fibrillation by Releasing TGF-β1 (Transforming Growth Factor-β1) and Interacting With Fibroblasts.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Blood Platelets; Clopidogrel; Fibroblasts; Humans; Hypertension; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Platelet Activation; Platelet Aggregation Inhibitors; Transforming Growth Factor beta1 | 2020 |
Activated Factor X Signaling Pathway via Protease-Activated Receptor 2 Is a Novel Therapeutic Target for Preventing Atrial Fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Factor Xa; Inflammation; Mice; Rats; Receptor, PAR-2; Rivaroxaban; Signal Transduction; Warfarin | 2021 |
Fus knockdown inhibits the profibrogenic effect of cardiac fibroblasts induced by angiotensin II through targeting Pax3 thereby regulating TGF-β1/Smad pathway.
Topics: Adult; Aged; Angiotensin II; Animals; Atrial Fibrillation; Cells, Cultured; Female; Fibroblasts; Fibrosis; Gene Knockdown Techniques; Humans; Male; Mice; Middle Aged; Myocardium; PAX3 Transcription Factor; RNA-Binding Protein FUS; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2021 |
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Angiotensin II; Animals; Antithrombins; Atrial Fibrillation; Body Mass Index; Catheter Ablation; Cohort Studies; Dabigatran; Dogs; Embolism; Factor Xa Inhibitors; Female; Genotype; Hemorrhage; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Middle Aged; Norepinephrine; Obesity; Polymorphism, Single Nucleotide; Retrospective Studies; Rivaroxaban; Stroke; Sympathectomy | 2017 |
Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.
Topics: Aminobutyrates; Angiotensin II; Animals; Atrial Fibrillation; Biphenyl Compounds; Fibrosis; Rats; Signal Transduction; Valsartan | 2022 |
PU.1 inhibition attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II by reducing TGF-β1/Smads pathway activation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cardiotonic Agents; Cells, Cultured; Fibrosis; Heterocyclic Compounds; Male; Mice; Mice, Inbred C57BL; Myocardium; Myofibroblasts; Proto-Oncogene Proteins; Signal Transduction; Smad3 Protein; Trans-Activators; Transforming Growth Factor beta | 2021 |
H
Topics: Angiotensin II; Atrial Fibrillation; Base Sequence; Connective Tissue Growth Factor; Fibroblasts; Fibrosis; Heart Atria; Humans; Hydrogen Sulfide; MicroRNAs | 2021 |
MFAP4 deletion attenuates the progression of angiotensin II-induced atrial fibrosis and atrial fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Fibrosis; Heart Atria; Humans; Mice; Phosphatidylinositol 3-Kinases | 2022 |
Role of the MAPKs/TGF-β1/TRAF6 signaling pathway in postoperative atrial fibrillation.
Topics: Angiotensin II; Atrial Appendage; Atrial Fibrillation; Connective Tissue Growth Factor; Extracellular Signal-Regulated MAP Kinases; Female; Fibrosis; Humans; Intracellular Signaling Peptides and Proteins; Male; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Middle Aged; Postoperative Complications; Prognosis; Rheumatic Heart Disease; RNA, Messenger; Severity of Illness Index; TNF Receptor-Associated Factor 6; Transforming Growth Factor beta1 | 2017 |
The crucial role of activin A/ALK4 pathway in the pathogenesis of Ang-II-induced atrial fibrosis and vulnerability to atrial fibrillation.
Topics: Activin Receptors, Type I; Activins; Adult; Aged; Angiotensin II; Animals; Atrial Fibrillation; Female; Fibrosis; Heart Atria; Humans; Male; Mice; Mice, Knockout; Middle Aged | 2017 |
miR‑132 in atrial fibrillation directly targets connective tissue growth factor.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Base Sequence; Connective Tissue Growth Factor; Dogs; Down-Regulation; Female; Fibroblasts; Humans; Male; MicroRNAs; Middle Aged; Myocardium; Rats; RNA, Messenger; Up-Regulation | 2017 |
Novel Role for the Immunoproteasome Subunit PSMB10 in Angiotensin II-Induced Atrial Fibrillation in Mice.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cysteine Endopeptidases; Disease Models, Animal; Gene Expression Regulation; I-kappa B Kinase; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Proteasome Endopeptidase Complex; Random Allocation; Reactive Oxygen Species; Reference Values; Sensitivity and Specificity; Signal Transduction; Up-Regulation | 2018 |
Atrial overexpression of microRNA-27b attenuates angiotensin II-induced atrial fibrosis and fibrillation by targeting ALK5.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Collagen; Fibrosis; Gene Expression; Heart Atria; Male; Mice, Inbred C57BL; MicroRNAs; Molecular Targeted Therapy; Phosphorylation; Plasminogen Activator Inhibitor 1; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein | 2018 |
YY1-induced upregulation of lncRNA KCNQ1OT1 regulates angiotensin II-induced atrial fibrillation by modulating miR-384b/CACNA1C axis.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Base Sequence; Calcium Channels, L-Type; Cells, Cultured; Gene Expression Regulation; HEK293 Cells; Humans; Male; Mice, Inbred C57BL; MicroRNAs; RNA Interference; RNA, Long Noncoding; Sequence Homology, Nucleic Acid; Signal Transduction; Up-Regulation; YY1 Transcription Factor | 2018 |
Distinct patterns of atrial electrical and structural remodeling in angiotensin II mediated atrial fibrillation.
Topics: Action Potentials; Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Biomarkers; Blood Pressure; Echocardiography; Electrocardiography; Immunohistochemistry; Male; Membrane Potentials; Mice; Myocytes, Cardiac | 2018 |
Immunoproteasome Subunit β5i Promotes Ang II (Angiotensin II)-Induced Atrial Fibrillation by Targeting ATRAP (Ang II Type I Receptor-Associated Protein) Degradation in Mice.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Disease Models, Animal; Fibrosis; Heart Atria; Immunoproteins; Mice; Oxidative Stress; Proteasome Endopeptidase Complex; Receptor, Angiotensin, Type 1 | 2019 |
NPR-C (Natriuretic Peptide Receptor-C) Modulates the Progression of Angiotensin II-Mediated Atrial Fibrillation and Atrial Remodeling in Mice.
Topics: Action Potentials; Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Disease Models, Animal; Disease Progression; Fibrosis; Heart Atria; Heart Rate; Hypertension; Male; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Cardiac; Receptors, Atrial Natriuretic Factor; Time Factors | 2019 |
Novel role of the clustered miR-23b-3p and miR-27b-3p in enhanced expression of fibrosis-associated genes by targeting TGFBR3 in atrial fibroblasts.
Topics: Angiotensin II; Atrial Fibrillation; Cell Proliferation; Collagen Type III; Fibroblasts; Fibrosis; Gene Expression Regulation; Heart Atria; Humans; MicroRNAs; Proteoglycans; Receptors, Transforming Growth Factor beta; Sick Sinus Syndrome; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1 | 2019 |
LncRNA PVT1 regulates atrial fibrosis via miR-128-3p-SP1-TGF-β1-Smad axis in atrial fibrillation.
Topics: Adult; Angiotensin II; Animals; Atrial Fibrillation; Cell Proliferation; Collagen Type I; Collagen Type II; Female; Fibroblasts; Fibrosis; Heart Atria; Humans; Male; Mice, Inbred C57BL; MicroRNAs; Middle Aged; RNA, Long Noncoding; Smad Proteins; Sp1 Transcription Factor; Transforming Growth Factor beta1 | 2019 |
Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Atria; Leptin; Male; Mice; Mice, Inbred C57BL; Myocardium; Rats; Rats, Sprague-Dawley; Rats, Zucker; Signal Transduction | 2013 |
Effects of irbesartan on gene expression revealed by transcriptome analysis of left atrial tissue in a porcine model of acute rapid pacing in vivo.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Biphenyl Compounds; Blotting, Western; Cell Line; Connective Tissue Growth Factor; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Heart Atria; Heart Rate; Irbesartan; Mice; Microarray Analysis; Myocytes, Cardiac; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine; Tetrazoles | 2013 |
Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacing.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Atrial Fibrillation; Atrial Natriuretic Factor; Atrial Remodeling; Blood Pressure; Cardiac Pacing, Artificial; Dogs; Fibrosis; Gap Junctions; GAP-43 Protein; Heart Atria; Inflammation; Interleukin-6; Kidney; Myocytes, Cardiac; Sympathectomy; Tumor Necrosis Factor-alpha | 2013 |
Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation.
Topics: Aged; Angiotensin II; Animals; Atrial Fibrillation; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Feedback, Physiological; Female; Heart Conduction System; Humans; Male; Methionine Sulfoxide Reductases; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; NADPH Oxidases; Oxidation-Reduction; Ryanodine Receptor Calcium Release Channel | 2013 |
PPAR-γ activation limits angiotensin II-mediated atrial remodeling: one drug fits all AF patients?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Atrial Remodeling; Humans; PPAR gamma; Receptor, Angiotensin, Type 1; Thiazolidinediones | 2014 |
Mechanisms with clinical implications for atrial fibrillation-associated remodeling: cathepsin K expression, regulation, and therapeutic target and biomarker.
Topics: Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Atrial Fibrillation; Biomarkers; Cardiac Pacing, Artificial; Case-Control Studies; Cathepsin K; Cells, Cultured; Disease Models, Animal; Female; Fibrosis; Heart Atria; Humans; Male; Middle Aged; Myocytes, Cardiac; NADPH Oxidases; p38 Mitogen-Activated Protein Kinases; Phosphopeptides; Phosphorylation; Procollagen; Protein Kinase Inhibitors; Rabbits; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Signal Transduction; Superoxides; Up-Regulation | 2013 |
From changes in local RAAS to structural remodeling of the left atrium: A beautiful cycle in atrial fibrillation.
Topics: Angiotensin II; Atrial Fibrillation; Atrial Remodeling; Female; Heart Atria; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Renin-Angiotensin System | 2015 |
Induction of atrial fibrillation by neutrophils critically depends on CD11b/CD18 integrins.
Topics: Analysis of Variance; Angiotensin II; Animals; Atrial Fibrillation; CD11b Antigen; CD18 Antigens; Electrophysiologic Techniques, Cardiac; Fluorescent Antibody Technique; Heart Atria; Immunoblotting; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Knockout; Neutrophils | 2014 |
Mkk4 is a negative regulator of the transforming growth factor beta 1 signaling associated with atrial remodeling and arrhythmogenesis with age.
Topics: Age Factors; Aged; Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Case-Control Studies; Cells, Cultured; Computer Simulation; Down-Regulation; Female; Fibrosis; Heart Rate; Humans; Male; MAP Kinase Kinase 4; Mice; Mice, Knockout; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Signal Transduction; Transfection; Transforming Growth Factor beta1 | 2014 |
Angiotensin II activates signal transducers and activators of transcription 3 via Rac1 in the atrial tissue in permanent atrial fibrillation patients with rheumatic heart disease.
Topics: Adult; Aged; Angiotensin II; Atrial Fibrillation; Atrial Remodeling; Female; Fibrosis; Heart Atria; Humans; Male; Middle Aged; Organ Size; rac1 GTP-Binding Protein; Rheumatic Heart Disease; Signal Transduction; STAT3 Transcription Factor | 2015 |
Renal denervation suppresses atrial fibrillation in a model of renal impairment.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Fibrillation; Autonomic Denervation; C-Reactive Protein; Catheter Ablation; Disease Models, Animal; Dogs; Fibrosis; Heart Atria; Hemodynamics; Interleukin-6; Ischemia; Kidney; Models, Cardiovascular; Norepinephrine; Renal Artery; Renal Artery Obstruction; Renin; Renin-Angiotensin System; Sympathetic Nervous System | 2015 |
TRIF promotes angiotensin II-induced cross-talk between fibroblasts and macrophages in atrial fibrosis.
Topics: Adaptor Proteins, Vesicular Transport; Angiotensin II; Animals; Atrial Fibrillation; Cell Communication; Cell Proliferation; Chemotaxis; Fibroblasts; Fibrosis; Gene Expression Regulation; Heart Atria; Humans; Losartan; Macrophages; Mice; Mice, Inbred C57BL; RNA, Small Interfering; Signal Transduction | 2015 |
Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensinogen; Atrial Fibrillation; Chymases; Echocardiography; Female; Gene Expression Regulation, Enzymologic; Heart Atria; Heart Valve Diseases; Humans; Male; Middle Aged; Myocardial Ischemia; RNA, Messenger; Up-Regulation; Ventricular Remodeling | 2015 |
Nitrated fatty acids suppress angiotensin II-mediated fibrotic remodelling and atrial fibrillation.
Topics: Action Potentials; Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Cell Transdifferentiation; Cells, Cultured; Connexin 43; Fibrosis; Heart Atria; Linoleic Acids; Mice; Mice, Inbred C57BL; Nitro Compounds; Smad2 Protein | 2016 |
MiR-30a regulates the atrial fibrillation-induced myocardial fibrosis by targeting snail 1.
Topics: 3' Untranslated Regions; Angiotensin II; Animals; Atrial Fibrillation; Binding Sites; Cardiomyopathies; Cell Adhesion Molecules; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Gene Expression Regulation; Male; MicroRNAs; Myocardium; Rabbits; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Snail Family Transcription Factors; Time Factors; Transcription Factors; Transfection | 2015 |
Cathepsin A mediates susceptibility to atrial tachyarrhythmia and impairment of atrial emptying function in Zucker diabetic fatty rats.
Topics: Action Potentials; Angiotensin II; Animals; Atrial Fibrillation; Atrial Function, Left; Atrial Remodeling; Bradykinin; Cathepsin A; Connexin 43; Diabetes Mellitus, Type 2; Disease Models, Animal; Fibrosis; Heart Rate; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; Protease Inhibitors; Rats, Zucker; Time Factors | 2016 |
Low-level carotid baroreflex stimulation suppresses atrial fibrillation by inhibiting left stellate ganglion activity in an acute canine model.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Baroreflex; Cardiac Pacing, Artificial; Carotid Arteries; Disease Models, Animal; Dogs; Electric Stimulation; Heart Atria; Models, Cardiovascular; Norepinephrine; Stellate Ganglion | 2016 |
The Role of the Rho/ROCK Pathway in Ang II and TGF-β1-Induced Atrial Remodeling.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Atrial Remodeling; Connective Tissue Growth Factor; Disease Models, Animal; Dogs; Female; Male; rho GTP-Binding Proteins; rho-Associated Kinases; Signal Transduction; Transforming Growth Factor beta1 | 2016 |
Membrane translocation of small GTPase Rac1 and activation of STAT1 and STAT3 in pacing-induced sustained atrial fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cardiac Pacing, Artificial; Cellular Structures; Extracellular Matrix; GTP Phosphohydrolases; Janus Kinase 2; Janus Kinases; Mitogen-Activated Protein Kinases; Models, Animal; rac1 GTP-Binding Protein; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Swine; Transcription, Genetic; Transcriptional Activation | 2008 |
Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cardiomegaly; Connexins; Enzyme Inhibitors; Fibrosis; Gap Junction alpha-5 Protein; Histone Deacetylase Inhibitors; Histone Deacetylases; Homeodomain Proteins; Hydroxamic Acids; Mice; Mice, Transgenic; Time Factors | 2008 |
Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiotonic Agents; Female; Heart; Heart Atria; Humans; Incidence; Isometric Contraction; Male; Muscle, Skeletal; Myocardium; Renin-Angiotensin System; Risk Factors | 2008 |
ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling.
Topics: Adult; Angiotensin II; Atrial Fibrillation; Atrioventricular Node; Case-Control Studies; Cohort Studies; Female; Heart Atria; Heart Block; Heart Diseases; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Ventricular Remodeling | 2009 |
Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation.
Topics: Aged; Angiotensin II; Animals; Animals, Newborn; Atrial Fibrillation; Cadherins; Connective Tissue Growth Factor; Connexin 43; Female; Fibroblasts; Fibrosis; Gene Expression Profiling; Heart Atria; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Transgenic; Middle Aged; Myocardium; Myocytes, Cardiac; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; rhoA GTP-Binding Protein; Signal Transduction; Transforming Growth Factor beta1 | 2010 |
Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury.
Topics: Analysis of Variance; Angiotensin II; Animals; Antioxidants; Atrial Fibrillation; Blood Pressure; Blotting, Western; Cardiomegaly; Cyclic N-Oxides; Echocardiography; Fibrosis; Heart Atria; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Oxidative Stress; Quinolines; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Smad2 Protein; Smad3 Protein; Spin Labels; Transforming Growth Factor beta1 | 2010 |
Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Heart Atria; Humans; Lymphocyte Activation; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Neutrophils; Peroxidase; Tyrosine | 2010 |
Effects of angiotensin receptor blockade on atrial electrical remodelling and the 'second factor' in a goat burst-paced model of atrial fibrillation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Electrophysiological Phenomena; Female; Goats; Heart Atria; Receptors, Angiotensin; Tetrazoles; Time Factors; Ventricular Function | 2010 |
Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Cells, Cultured; Collagen; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Fibrosis; Losartan; Models, Animal; Myocardium; Rabbits; Receptor, Angiotensin, Type 1; RNA, Small Interfering; Smad7 Protein; Transforming Growth Factor beta1; Ubiquitin-Protein Ligases | 2011 |
Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation.
Topics: Aged; Angiotensin II; Animals; Animals, Newborn; Atrial Fibrillation; Blotting, Western; Cells, Cultured; Collagen; Connective Tissue Growth Factor; Enzyme-Linked Immunosorbent Assay; Female; Fluorescent Antibody Technique, Indirect; Heart Atria; Humans; Immunohistochemistry; In Vitro Techniques; Male; Mice; Myocytes, Cardiac; Oligonucleotide Array Sequence Analysis; Protein-Lysine 6-Oxidase; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes.
Topics: Aged; Aged, 80 and over; Angiotensin II; Animals; Atrial Fibrillation; Cells, Cultured; Collagen; Connective Tissue Growth Factor; Disease Models, Animal; Extracellular Matrix; Female; Fibroblasts; Heart Atria; Humans; Male; Middle Aged; Myocytes, Cardiac; Rats; Rats, Wistar; RNA, Messenger; Swine | 2011 |
Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Blotting, Western; Connective Tissue Growth Factor; Disease Models, Animal; Dogs; Extracellular Matrix; Female; Heart Atria; Imidazoles; Real-Time Polymerase Chain Reaction; Signal Transduction; Tetrazoles; Up-Regulation | 2012 |
Atrial fibrillation and fibrosis: role of connective tissue growth factor.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Connective Tissue Growth Factor; Female; Heart Atria; Imidazoles; Tetrazoles | 2012 |
Effect of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing.
Topics: Aldosterone; Analysis of Variance; Angiography; Angiotensin II; Animals; Atrial Fibrillation; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Enzyme-Linked Immunosorbent Assay; Heart Atria; Heart Conduction System; Kidney; Renin; Renin-Angiotensin System; Sympathectomy | 2012 |
Circulating and local renin-angiotensin-aldosterone system express differently in atrial fibrillation patients with different types of mitral valvular disease.
Topics: Adult; Aldosterone; Angiotensin II; Atrial Fibrillation; Female; Heart Rate; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Regression Analysis; Renin; Renin-Angiotensin System | 2013 |
Improved neurohormonal markers of ventricular function after restoring sinus rhythm by the Maze procedure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Atrial Fibrillation; Atrial Natriuretic Factor; Chronic Disease; Cryosurgery; Female; Follow-Up Studies; Hemodynamics; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Postoperative Complications; Vasopressins; Ventricular Dysfunction, Left; Ventricular Function, Left | 2003 |
Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Atrial Fibrillation; bcl-2-Associated X Protein; Biomarkers; Cardiac Pacing, Artificial; Caspase 3; Caspases; DNA Fragmentation; Dogs; Enalapril; Heart Atria; Heart Failure; In Situ Nick-End Labeling; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2003 |
Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease.
Topics: Adult; Aged; Angiotensin II; Atrial Fibrillation; Atrial Function, Left; Atrial Function, Right; Female; Heart Atria; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Receptors, Angiotensin | 2003 |
Defining "culprit mechanisms" in arrhythmogenic cardiac remodeling.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Dogs; Fibrosis; Heart Atria; Heart Failure; Humans; Mice; Mice, Transgenic; Models, Animal; Myocardium; Transforming Growth Factor beta; Transforming Growth Factor beta1; Ventricular Remodeling | 2004 |
Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Atrial Fibrillation; Atrial Function, Left; Atrial Function, Right; Heart Atria; Heart Valve Diseases; Humans; Mitral Valve; Receptors, Angiotensin | 2004 |
Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Bradykinin; Death, Sudden; Disease Models, Animal; Female; Gene Targeting; Heart Block; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myosin Heavy Chains; Peptidyl-Dipeptidase A; Promoter Regions, Genetic; Recombination, Genetic; Tissue Distribution | 2004 |
[Molecular biology of the heart atrium. New insights into the pathophysiology of atrial fibrillation as well as its clinical implications].
Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytokines; Gene Expression Regulation; Heart Atria; Humans; Matrix Metalloproteinases; Molecular Biology; Signal Transduction | 2004 |
Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Fibrillation; Atrial Natriuretic Factor; Cardiac Pacing, Artificial; Cardiomegaly; Cell Size; Chronic Disease; Connexin 43; Connexins; Female; Gap Junction alpha-5 Protein; Goats; Heart Block; Heart Conduction System; Hemodynamics; Hypertrophy; Myocytes, Cardiac; Neural Conduction; Norepinephrine; Refractory Period, Electrophysiological | 2005 |
Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: potential role for early remodeling in atrial fibrillation.
Topics: Aged; Angiotensin II; Atrial Fibrillation; Calcium Signaling; Connexin 43; Connexins; Electrophysiology; Female; Gap Junction alpha-5 Protein; Heart Atria; Humans; In Vitro Techniques; Male; Middle Aged; Myocytes, Cardiac | 2006 |
Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in guinea pig atrial myocytes.
Topics: Action Potentials; Angiotensin II; Animals; Atrial Fibrillation; Delayed Rectifier Potassium Channels; Electrophysiology; Guinea Pigs; Heart Atria; Kinetics; Muscle Cells; Patch-Clamp Techniques; Receptor, Angiotensin, Type 1; Type C Phospholipases | 2006 |
Do cardiac neuropeptides play a role in the occurrence of atrial fibrillation after coronary bypass surgery?
Topics: Adrenergic beta-Antagonists; Aging; Angiotensin II; Atrial Fibrillation; Coronary Artery Bypass; Diabetes Complications; Echocardiography; Female; Humans; Male; Middle Aged; Mitral Valve; Myocardium; Neuropeptide Y; Postoperative Period; Prospective Studies; Sodium; Stroke Volume; Substance P | 2007 |
Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Bundle of His; Cardiac Output; Cardiac Pacing, Artificial; Disease Models, Animal; Female; Kaplan-Meier Estimate; Matrix Metalloproteinases; Myocytes, Cardiac; Refractory Period, Electrophysiological; Renin-Angiotensin System; Sheep; Time Factors; Tissue Inhibitor of Metalloproteinases | 2007 |
Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cell Culture Techniques; Endomyocardial Fibrosis; Fibroblasts; Heart Atria; HSP72 Heat-Shock Proteins; Hyperthermia, Induced; Inositol Phosphates; Male; Myocardium; Rats; Rats, Sprague-Dawley; RNA, Small Interfering | 2007 |
Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cells, Cultured; Fibroblasts; Heart Atria; Humans; Losartan; Muscle Cells; Phosphorylation; rac1 GTP-Binding Protein; Rats; Rats, Wistar; Signal Transduction; Simvastatin; STAT3 Transcription Factor; Ventricular Remodeling | 2008 |
Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Cell Line; Disease Models, Animal; Electric Stimulation; Gene Expression; Myocytes, Cardiac; Renin-Angiotensin System; Swine; Up-Regulation | 2008 |
Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Fibrillation; Atrial Function; Benzimidazoles; Biphenyl Compounds; Captopril; Dogs; Female; Heart Conduction System; Male; Myocardium; Pacemaker, Artificial; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Sinoatrial Node; Tetrazoles; Time Factors | 2000 |
Elevations in antidiuretic hormone and aldosterone as possible causes of fluid retention in the Maze procedure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Atrial Fibrillation; Atrial Natriuretic Factor; Coronary Artery Bypass; Female; Heart Atria; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Postoperative Complications; Vasopressins; Water-Electrolyte Balance | 2001 |
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Dogs; Electrophysiology; Enalapril; Endomyocardial Fibrosis; Heart Atria; Heart Failure; Hemodynamics; Hydralazine; Isosorbide Dinitrate; Mitogen-Activated Protein Kinases; Renin-Angiotensin System; Signal Transduction; Tachycardia, Ventricular | 2001 |
Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Atrial Function; Atrial Natriuretic Factor; Blood Pressure; Electrophysiologic Techniques, Cardiac; Female; Follow-Up Studies; Heart Atria; Models, Animal; Sheep | 2001 |